Jan. 4, 2012
/PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in
January 8 through 13
Representatives of Antigen Express will be available over the course of the conference to meet with prospective partners, collaborators, and investors in respect of the Antigen Express proprietary platform immunotherapeutic vaccine technologies.
, Generex President & Chief Executive Officer, has commented: "In particular, the recently announced positive interim clinical data from our Phase 2b study in HER-2 expressing breast cancer subjects makes the time ripe for discussions with prospective partners and collaborations in respect of a Phase 3 study of the breast cancer vaccine."
Interested parties are invited to contact:
Seahawk Capital Partners, Inc. 646-599-6222
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.
The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.